Alpha Cognition Inc. Comm...

NASDAQ: ACOG · Real-Time Price · USD
5.99
0.47 (8.51%)
At close: May 01, 2025, 3:59 PM
5.98
-0.17%
After-hours: May 01, 2025, 04:05 PM EDT
8.51%
Bid 5.72
Market Cap 93.03M
Revenue (ttm) n/a
Net Income (ttm) -14.63M
EPS (ttm) -2.02
PE Ratio (ttm) -2.97
Forward PE n/a
Analyst Buy
Ask 6.58
Volume 70,220
Avg. Volume (20D) 62,072
Open 5.52
Previous Close 5.52
Day's Range 5.32 - 6.19
52-Week Range 3.75 - 7.00
Beta 2.51

About ACOG

Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treat...

IPO Date n/a
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ACOG
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ACOG stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 233.89% from the latest price.

Stock Forecasts
3 months ago
+0%
Alpha Cognition shares are trading higher after th... Unlock content with Pro Subscription